logo conference-reports

Conference Reports

Educational funding by logo MSD Oncology

ELCC 2019 - Pooled data from KEYNOTE trials confirm safety and efficacy of pembrolizumab in elderly patients with NSCLC

Efficacy of checkpoint-inhibitor pembrolizumab in NSCLC extends to patients beyond 75 years of age